{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-002764","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.564765+00:00","generated_at":"2026-06-19T21:35:04.044598+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vanda Q4/FY2022: revenue $64.5M/$254.4M, net income down; patent litigation continues","bullets":["Q4 total net product sales $64.5M (-5% YoY); FY2022 sales $254.4M (-5% YoY). Net income Q4 $6.9M ($0.12 diluted) vs $7.1M; FY net income $6.3M ($0.11) down from $33.2M ($0.58) in 2021.","HETLIOZ sales Q4 $40.1M (-9% YoY) due to reimbursement challenges; Fanapt $24.4M (+2% YoY).","Teva launched generic HETLIOZ at risk; appeal in patent litigation scheduled for March 14, 2023. New patent infringement lawsuits filed against Teva and Apotex.","Plans to submit NDA for tradipitant (gastroparesis) and sNDA for Fanapt (bipolar I disorder) in H1 2023. Phase III motion sickness results expected mid-2023.","No 2023 financial guidance provided due to uncertainties from HETLIOZ patent litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-002764","json":"https://secwatch.observer/filing/0001628280-23-002764.json","markdown":"https://secwatch.observer/filing/0001628280-23-002764.md","text":"https://secwatch.observer/filing/0001628280-23-002764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/0001628280-23-002764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/vnda-20230208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:35:04.044598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef2aad6e54d810b4d8243708bfb2665aeb976b72","claim":"Vanda Pharmaceuticals Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $254.4 million, net income $6.3 million, EPS $0.11.","evidence_excerpt":"Total net product sales from HETLIOZ ® and Fanapt ® were $64.5 million in the fourth quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/0001628280-23-002764-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$254.4 million"},{"label":"Net income","value":"$6.3 million"},{"label":"EPS","value":"$0.11"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ef2aad6e54d810b4d8243708bfb2665aeb976b72","claim":"Vanda Pharmaceuticals Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $254.4 million, net income $6.3 million, EPS $0.11.","evidence_excerpt":"Total net product sales from HETLIOZ ® and Fanapt ® were $254.4 million for the full year 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/0001628280-23-002764-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$254.4 million"},{"label":"Net income","value":"$6.3 million"},{"label":"EPS","value":"$0.11"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}